|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contradictory data about the impact of the rs738409 steatosis-related polymorphism within PNPLA3 gene on liver fibrosis progression in HIV/hepatitis C virus (HIV/HCV)-coinfected patients have been reported.
|
27973562 |
2016 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 genotypes were also associated with higher risk of developing liver fibrosis and cirrhosis in dominant (aOR: 1.98, P=2.20*10-5; aOR: 1.67, P=0.008, respectively) and recessive (aOR: 3.94, P=5.16*10-5; aOR: 3.02, P=0.003, respectively) models.
|
28338112 |
2017 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate models adjusting for histologic features of nonalcoholic steatohepatitis and liver fibrosis, PNPLA3 I148M is associated with a decrease in VLDL particle size.
|
28362682 |
2019 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fetuin B is independently and negatively associated with non-invasive markers of liver fibrosis and PNPLA3 status in NAFLD patients but does not show a correlation with the hepatic lipid content.
|
28914407 |
2017 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study assessed the contribution of the PNPLA3 rs738409 polymorphism with regard to the steatosis and degree of liver fibrosis in Brazilian patients diagnosed with chronic hepatitis C.
|
29258449 |
2017 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism appears to be related to the increased progression of liver fibrosis in HCV infected patients.
|
29674183 |
2018 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rs738409 C>G p.I148M variant in the patatin-like phospholipase domain containing 3 (PNPLA3)-gene promotes triglyceride accumulation in hepatocytes and hepatic stellate cell activation and has previously been linked to hepatic steatosis/liver fibrosis.
|
29956823 |
2018 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
|
30139224 |
2018 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using a newly developed and validated assay for PNPLA3, we explored the prevalence of gene polymorphisms in a cohort of HCV/HIV-coinfected individuals to determine whether there was an association with insulin resistance or hepatic fibrosis.
|
30218427 |
2018 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PNPLA3 G was also associated with increased levels of ALT, except in participants with Dominican and South American backgrounds, and with liver fibrosis.
|
30743004 |
2019 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
These genetic variations also did not mediate the effect of <i>PNPLA3 rs738409</i> SNP for liver developing liver fibrosis or liver cirrhosis.
|
30875804 |
2019 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with nonalcoholic steatohepatitis (NASH), PNPLA3 GG compared to CC was associated with higher AST levels [38.4±25.3 versus 36.7±40.1IU/L, p=0.0395)] and with the presence of liver fibrosis (≥F2 fibrosis, p=0.0272).
|
31054980 |
2020 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiple logistic regression was performed to investigate the association of PNPLA3 G allele with clinical and laboratory variables and with hepatic fibrosis/steatosis.
|
31377187 |
2019 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aims to assess the impact of IL28B rs8099917 polymorphism on CHC genotype 4 (G4) susceptibility and liver fibrosis progression individually; and in combination with PNPLA3 rs738409.<b>Patients and methods:</b> IL28B rs8099917 and PNPLA3 rs738409 were genotyped in 150 Egyptian CHC patients and 175 healthy controls using real-time PCR.<b>Results:</b> IL28B rs8099917 genotype distribution significantly differs in healthy individuals versus CHC patients (<i>p</i> = .018); and in low versus advanced fibrosis IL28B (<i>p</i> = .013).
|
31793339 |
2019 |